259 related articles for article (PubMed ID: 11162826)
1. Kinetic analyses of stability of simple and complex retroviral vectors.
Higashikawa F; Chang L
Virology; 2001 Feb; 280(1):124-31. PubMed ID: 11162826
[TBL] [Abstract][Full Text] [Related]
2. Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein.
Bartz SR; Vodicka MA
Methods; 1997 Aug; 12(4):337-42. PubMed ID: 9245614
[TBL] [Abstract][Full Text] [Related]
3. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1.
Stitz J; Buchholz CJ; Engelstädter M; Uckert W; Bloemer U; Schmitt I; Cichutek K
Virology; 2000 Jul; 273(1):16-20. PubMed ID: 10891403
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent transduction of vesicular stomatitis virus G protein-pseudotyped retrovirus vector into human solid tumor cell lines and murine fibroblasts.
Arai T; Takada M; Ui M; Iba H
Virology; 1999 Jul; 260(1):109-15. PubMed ID: 10405362
[TBL] [Abstract][Full Text] [Related]
5. Rhesus monkey model for fetal gene transfer: studies with retroviral- based vector systems.
Tarantal AF; O'Rourke JP; Case SS; Newbound GC; Li J; Lee CI; Baskin CR; Kohn DB; Bunnell BA
Mol Ther; 2001 Feb; 3(2):128-38. PubMed ID: 11237669
[TBL] [Abstract][Full Text] [Related]
6. Gene transfer in human skin with different pseudotyped HIV-based vectors.
Hachiya A; Sriwiriyanont P; Patel A; Saito N; Ohuchi A; Kitahara T; Takema Y; Tsuboi R; Boissy RE; Visscher MO; Wilson JM; Kobinger GP
Gene Ther; 2007 Apr; 14(8):648-56. PubMed ID: 17268532
[TBL] [Abstract][Full Text] [Related]
7. Lentiviral vectors pseudotyped with glycoproteins from Ross River and vesicular stomatitis viruses: variable transduction related to cell type and culture conditions.
Kahl CA; Pollok K; Haneline LS; Cornetta K
Mol Ther; 2005 Mar; 11(3):470-82. PubMed ID: 15727944
[TBL] [Abstract][Full Text] [Related]
8. MLV-derived retroviral vectors selective for CD4-expressing cells and resistant to neutralization by sera from HIV-infected patients.
Stitz J; Steidl S; Merget-Millitzer H; König R; Müller P; Nocken F; Engelstädter M; Bobkova M; Schmitt I; Kurth R; Buchholz CJ; Cichutek K
Virology; 2000 Feb; 267(2):229-36. PubMed ID: 10662618
[TBL] [Abstract][Full Text] [Related]
9. Production and concentration of pseudotyped HIV-1-based gene transfer vectors.
Reiser J
Gene Ther; 2000 Jun; 7(11):910-3. PubMed ID: 10849549
[TBL] [Abstract][Full Text] [Related]
10. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
11. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.
Haglund K; Forman J; Kräusslich HG; Rose JK
Virology; 2000 Mar; 268(1):112-21. PubMed ID: 10683333
[TBL] [Abstract][Full Text] [Related]
12. Selective gene transfer to T lymphocytes using coreceptor-specific [MLV(HIV)] pseudotype vectors in a transgenic mouse model.
Schüle S; Steidl S; Panitz S; Coulibaly C; Kalinke U; Cichutek K; Schweizer M
Virology; 2006 Jul; 351(1):237-47. PubMed ID: 16650881
[TBL] [Abstract][Full Text] [Related]
13. Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells.
Strang BL; Ikeda Y; Cosset FL; Collins MK; Takeuchi Y
Gene Ther; 2004 Apr; 11(7):591-8. PubMed ID: 14724689
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.
Chang LJ; Urlacher V; Iwakuma T; Cui Y; Zucali J
Gene Ther; 1999 May; 6(5):715-28. PubMed ID: 10505094
[TBL] [Abstract][Full Text] [Related]
15. Antibody-dependent gene transduction using gammaretroviral and lentiviral vectors pseudotyped with chimeric vesicular stomatitis virus glycoprotein.
Kameyama Y; Kawabe Y; Ito A; Kamihira M
J Virol Methods; 2008 Oct; 153(1):49-54. PubMed ID: 18606189
[TBL] [Abstract][Full Text] [Related]
16. Preparation and quantification of pseudotyped retroviral vector.
Yu H; Kwon YJ
Methods Mol Biol; 2008; 433():1-16. PubMed ID: 18679614
[TBL] [Abstract][Full Text] [Related]
17. A novel lentivirus vector derived from apathogenic simian immunodeficiency virus.
Stitz J; Mühlebach MD; Blömer U; Scherr M; Selbert M; Wehner P; Steidl S; Schmitt I; König R; Schweizer M; Cichutek K
Virology; 2001 Dec; 291(2):191-7. PubMed ID: 11878888
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells.
Strang BL; Takeuchi Y; Relander T; Richter J; Bailey R; Sanders DA; Collins MK; Ikeda Y
J Virol; 2005 Feb; 79(3):1765-71. PubMed ID: 15650201
[TBL] [Abstract][Full Text] [Related]
19. Truncation of the human immunodeficiency virus-type-2 envelope glycoprotein allows efficient pseudotyping of murine leukemia virus retroviral vector particles.
Höhne M; Thaler S; Dudda JC; Groner B; Schnierle BS
Virology; 1999 Aug; 261(1):70-8. PubMed ID: 10441556
[TBL] [Abstract][Full Text] [Related]
20. High efficiency in vitro gene transfer into vascular tissues using a pseudotyped retroviral vector without pseudotransduction.
Yu H; Eton D; Wang Y; Kumar SR; Tang L; Terramani TT; Benedict C; Hung G; Anderson WF
Gene Ther; 1999 Nov; 6(11):1876-83. PubMed ID: 10602383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
